Monday, October 27, 2025
- 10:30AM-12:30PM
-
Abstract Number: 1236
Vestibulocortical Stimulation via Caloric Irrigation in Nociplastic Disease: Therapeutic Effects on Pain, Autonomic Functioning & Quality of Life Measures
(1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster- 10:30AM-12:30PM
-
Abstract Number: 1171
VEXAS Syndrome Under the Lens: A prospective analysis of temporal disease patterns, biomarker Dynamics, and therapeutic efficacy
(1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II- 10:30AM-12:30PM
-
Abstract Number: 1176
VISIBLE Post-Inflammatory Pigmentation Journeys: Exploring the Impact of Pigmentation
(1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II- 10:30AM-12:30PM
-
Abstract Number: 1490
Vitamin D Deficiency and Its Relationship with Inflammatory Biomarkers in SLE: A Focus on Neutrophil-to-Lymphocyte Ratio
(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II- 10:30AM-12:30PM
-
Abstract Number: 1544
Voclosporin in Lupus Nephritis: Meta-Analysis of 6-Month and 1-Year Efficacy with 1-Year Safety Outcomes
(1517–1552) Systemic Lupus Erythematosus – Treatment Poster II- 10:30AM-12:30PM
-
Abstract Number: 1408
When Damage and Disability Diverge: Unraveling Sex-Based Drivers of Axial Spondyloarthritis Burden
(1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II- 10:30AM-12:30PM
-
Abstract Number: 1279
Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
(1272–1305) Pediatric Rheumatology – Clinical Poster II- 10:30AM-12:30PM
-
Abstract Number: 1487
Whole Health Empowerment for Endotypes of Lupus (WHEEL) Program: User Testing Findings on Feasibility, Acceptability, and Opportunities for Intervention Refinement
(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II- 10:30AM-12:30PM
-
Abstract Number: 1470
Why Do Some Lupus Patients Skip Their Mycophenolate Mofetil? A Multi-Factorial Assessment of Patient Compliance
(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II- 10:30AM-12:30PM
-
Abstract Number: 1612
Window of opportunity with tocilizumab therapy in giant cell arteritis. Multicenter study of 471 patients of clinical practice
(1612–1632) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II- 10:30AM-12:30PM
-
Abstract Number: 1155
Zasocitinib (TAK-279), an Investigational, Oral, Allosteric, Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Efficacy Analysis by Baseline Characteristics from a Randomized Phase 2b Trial
(1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II- 10:45AM-11:00AM
-
Abstract Number: 0894
Altered B cell subpopulations in Giant Cell Arteritis
Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: GCA From Bench to Bedside (0891–0896)- 10:45AM-11:00AM
-
Abstract Number: 0876
Effect of QX002N on Clinical and Radiographic Outcomes in Ankylosing Spondylitis: Results from a Phase III Randomized, Double-blind, Placebo-Controlled Study
Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Therapies (0873–0878)- 10:45AM-11:00AM
-
Abstract Number: 0858
IgA Anti-β2GPI Antibodies Drive Proatherogenic Myeloid Activation and Vascular Dysfunction in APS
Abstracts: Antiphospholipid Syndrome (0855–0860)- 10:45AM-11:00AM
-
Abstract Number: 0864
Immunophenotyping Reveals Upregulated IL-9R on Circulating T and B Cells in Dermatomyositis